Similarly, in this study we found that the deletion of PTPN2 in immunogenic AT3-OVA tumors using CRISPR ribonucleoprotein (RNP)-based genome editing (Supplementary Fig. 13) had no significant effect on tumor growth (Supplementary Fig. 14). The gene discussed is PTPN2; the disease is neoplasm.